A basket study of ALPN-303 renal, hematologic, and/or dermatologic indications
Latest Information Update: 23 Nov 2022
At a glance
- Drugs Povetacicept (Primary)
- Indications Haematological disorders; Renal impairment; Skin disorders
- Focus Therapeutic Use
- 14 Nov 2022 According to an Alpine Immune Sciences media release, initial clinical data from the basket studies expected in late 2023.
- 14 Nov 2022 According to an Alpine Immune Sciences media release, data from this study were presented at the R&D Day on Sep 2022.
- 11 Aug 2022 According to an Alpine Immune Sciences media release, this trial is expected to begin in the first half of 2023 and initial clinical data from the basket trials expected in the second half of 2023.